|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
American Cancer Society. Cancer Facts
& Figures 2011. American Cancer Society; Atlanta: 2011
|
|
3
|
Davis-Dusenbery BN and Hata A: microRNA in
cancer: the involvement of aberrant microRNA biogenesis regulatory
pathways. Genes Cancer. 1:1100–1114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee JW, Choi CH, Choi JJ, et al: Altered
microRNA expression in cervical carcinomas. Clin Cancer Res.
14:2535–2542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He L and Hannon GJ: MicroRNAs: small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Uesugi A, Kozaki K, Tsuruta T, et al: The
tumor suppressive microRNA miR-218 targets the mTOR component
Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res.
71:5765–5778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tatarano S, Chiyomaru T, Kawakami K, et
al: miR-218 on the genomic loss region of chromosome 4p15.31
functions as a tumor suppressor in bladder cancer. Int J Oncol.
39:13–21. 2011.PubMed/NCBI
|
|
12
|
Wu DW, Cheng YW, Wang J, Chen CY and Lee
H: Paxillin predicts survival and relapse in non-small cell lung
cancer by microRNA-218 targeting. Cancer Res. 70:10392–10401. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song L, Huang Q, Chen K, et al: miR-218
inhibits the invasive ability of glioma cells by direct
downregulation of IKK-β. Biochem Biophys Res Commun. 402:135–140.
2010.PubMed/NCBI
|
|
14
|
Alajez NM, Lenarduzzi M, Ito E, et al:
MiR-218 suppresses nasopharyngeal cancer progression through
downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res.
71:2381–2391. 2011. View Article : Google Scholar
|
|
15
|
Tie J, Pan Y, Zhao L, et al: MiR-218
inhibits invasion and metastasis of gastric cancer by targeting the
Robo1 receptor. PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu J, Wang Y, Dong R, Huang X, Ding S and
Qiu H: Circulating microRNA-218 was reduced in cervical cancer and
correlated with tumor invasion. J Cancer Res Clin Oncol.
138:671–674. 2012. View Article : Google Scholar
|
|
17
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu D, Wu Y, Wang Y, et al: CREPT
accelerates tumorigenesis by regulating the transcription of
cell-cycle-related genes. Cancer Cell. 21:92–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cancer Research UK. Cervical cancer
survival statistics. Let’s Beat Cancer Sooner. http://info.cancerresearchuk.org/cancerstats/types/cervix/survival/.
Accessed, April 2011
|
|
20
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar
|
|
21
|
Janssen HL, Reesink HW, Lawitz EJ, et al:
Treatment of HCV infection by targeting microRNA. N Engl J Med.
368:1685–1694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang R, Ma J, Wu Q, et al: Functional role
of miR-34 family in human cancer. Curr Drug Targets. 14:1185–1191.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fish JE, Wythe JD, Xiao T, et al: A
Slit/miR-218/Robo regulatory loop is required during heart tube
formation in zebrafish. Development. 138:1409–1419. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao C, Zhang Z, Liu W, Xiao S, Gu W and Lu
H: Reduced microRNA-218 expression is associated with high nuclear
factor kappa B activation in gastric cancer. Cancer. 116:41–49.
2009.PubMed/NCBI
|
|
25
|
Leath CA III and Straughn JM Jr:
Chemotherapy for advanced and recurrent cervical carcinoma: results
from cooperative group trials. Gynecol Oncol. 129:251–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scatchard K, Forrest JL, Flubacher M,
Cornes P and Williams C: Chemotherapy for metastatic and recurrent
cervical cancer. Cochrane Database Syst Rev.
10:CD0064692012.PubMed/NCBI
|
|
27
|
He X, Dong Y, Wu CW, et al: MicroRNA-218
inhibits cell cycle progression and promotes apoptosis in colon
cancer by downregulating BMI1 polycomb ring finger oncogene. Mol
Med. 18:1491–1498. 2012.PubMed/NCBI
|
|
28
|
Ziliak D, Gamazon ER, Lacroix B, Kyung Im
H, Wen Y and Huang RS: Genetic variation that predicts platinum
sensitivity reveals the role of miR-193b* in
chemotherapeutic susceptibility. Mol Cancer Ther. 11:2054–2061.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei J, Gao W, Zhu CJ, et al:
Identification of plasma microRNA-21 as a biomarker for early
detection and chemosensitivity of non-small cell lung cancer. Chin
J Cancer. 30:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
|
